News Headlines

  1. The United Laboratories And Novo Nordisk Announce Exclusive License Agreement For UBT251, A GLP-1/GIP/Glucagon Triple Receptor Agonist 3/24/2025

    The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.

  2. AstraZeneca To Invest $2.5B In New Global Strategic R&D Centre, Biotech Agreements And Manufacturing In Beijing 3/21/2025

    AstraZeneca today announced an investment of $2.5B in Beijing to establish its sixth global strategic R&D centre together with major research and manufacturing agreements that will further advance life sciences in China.

  3. Upperton Continues Strategic Growth With The Appointment Of Michael Mellor-Clark As Chief Commercial Officer 3/20/2025

    Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), continues its growth following the build of a new sterile manufacturing facility with the appointment of Michael Mellor-Clark as Chief Commercial Officer (CCO).

  4. Bionova Scientific Appoints Bionique Testing Laboratories As Preferred Provider For Mycoplasma Testing Services For Biologics Manufacturing 3/20/2025

    Bionova Scientific, a boutique commercial-scale biologics contract development and manufacturing organization (CDMO), announced that Bionique Testing Laboratories, a leading Contract Research Organization (CRO), has been appointed as the preferred provider for mycoplasma testing services supporting the efficient manufacturing of biologics. Both are subsidiaries of the global Japanese conglomerate Asahi Kasei Corporation's medical division.

  5. Eckert & Ziegler And AtomVie Sign A Global Agreement For Lutetium-177 Supply 3/20/2025

    Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. (AtomVie) today announced a global supply agreement. Eckert & Ziegler will provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177, Theralugand) to support AtomVie’s CDMO activities for radiopharmaceutical manufacturing.

  6. ABVC BioPharma Maintains Lucrative Global Licensing Agreements And Promising CDMO Acquisition, Strengthening Growth Potential 3/19/2025

    ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, provides an update on its cash milestone payment receivables per global licensing agreements and $60M CDMO acquisition, reinforcing its strategic positioning for long-term growth.

  7. Cellares And Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program For Rese-Cel Using The Cell Shuttle Platform 3/19/2025

    Cellares, the first Integrated Development and Manufacturing Organization (IDMO), has concluded the Technology Adoption Program (TAP) on its automated cell therapy manufacturing Cell Shuttle for resecabtagene autoleucel, (rese-cel, previously known as CABA-201).

  8. Fujirebio Enhances Supply Chain Operations With Kinaxis 3/19/2025

    Kinaxis, a global leader in end-to-end supply chain orchestration, today announced that Fujirebio Inc., a Japanese multinational biotechnology company, is using Kinaxis and its AI-powered supply chain orchestration platform Maestro to enhance and optimize its supply chain operations.

  9. Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System To Accelerate The Development Of Cell Therapies 3/19/2025

    Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx’s PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova.

  10. Porton Advanced Announces Collaboration With Eureka Therapeutics To Accelerate T Cell Therapy Development 3/19/2025

    Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.